



Introduction



Spiromastixone J

- Depsidone natural product similar to Diploicin, isolated from deep-sea Spiromastix sp. fungus collected at 2,869 meter depth by autonomous remotely-operated vehicle¹
- Isolated in 0.022% yield after three consecutive column chromatography separations performed on 58.4 g of extract after 50 days of fermentation¹
- Exhibits single digit micromolar IC_{50} s towards multi-drug resistant Gram-Positive Bacteria such as MRSA¹

<u>Table 1: Reported IC₅₀s of Spiromastixone J</u>

| Bacterial Strain | | Resistance Phenotype | IC50 (μM) | | |
|---------------------|------------|-------------------------|-------------|---------|--|
| | | | Mastixone J | Levoflo | |
| S. aureus | ATCC 33591 | MRSA | 2 | 0.2 | |
| | 15 | MSSA | 2 | 0.12 | |
| | 12-28 | MSSA | 4 | 0.2 | |
| | 12-33 | MRSA | 4 | 64 | |

Retrosynthetic Analysis²



The above retrosynthetic analysis shows the heavy reliance on a large presence of Key Intermediate 1 (resorcilate).

Studies Toward the Total Synthesis of Spiromastixone J

Brandon Miller and Dr. Pier Cirillo

University of New Haven: Department of Chemistry and Chemical Engineering



| Experimental Results | | | | | | | | | | |
|---|----------------------|----------------------|-------------|--------------------|-----------------------|----------|-------------|-------------|--|--|
| Scheme 1: Consecutive Claisen Condensations on Dioxinone ³ | | | | | | | | | | |
| $ \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \end{array}{} \\ \\ \end{array}{} \\ \end{array}{} \\ \end{array}{} \\ \\ \\ \end{array}{} \\ \\ \end{array}{} \\ \\ \end{array}{} \\ \end{array}{} \\ \\ \\ \\ \end{array}{} \\ \end{array}{} \\ \end{array}{} \\ \\ \\ \end{array}{} \\ \end{array}{} \\ \\ \\ \\ \end{array}{} \\ \end{array}{} \\ \end{array}{} \\ \\ \\ \\ \end{array}{} \\ \end{array}{} \\ \\ \\ \\ \\ \end{array}{} \\ \end{array}{} \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$ | | | | | | | | | | |
| produce a sufficient amount of Key Intermediate 1. | | | | | | | | | | |
| Scheme 2: Diels-Alder Cycloaddition ^{4,5} $\downarrow \downarrow $ | | | | | | | | | | |
| | R ¹ Group | R ² Group | Ra Diene | ntio Dienophile | Solvent | Catalyst | Temperature | Result | | |
| | Methyl | TBDMS | 1 | 1 | None | None | RT | No Reaction | | |
| | Methyl | TBDMS | 1 | 2 | None | None | RT | No Reaction | | |
| | Methyl | TBDMS | 2 | 1 | None | None | RT | No Reaction | | |
| | Methyl | TBDMS | 2 | 1 | None | None | 0 C | No Reaction | | |
| | Methyl | TBDMS | 1 | 2 | Toluene | None | 80 C | No Reaction | | |
| | Methyl | TBDMS | 1 | 1 | None | | 0 C | No Reaction | | |
| | Methyl | | 1 | 1 | None Diathyl Ethar | | | No Reaction | | |
| | Methyl | TROMS | 1 | 1 | Diethyl Ether | | кі 60 С | No Reaction | | |
| | Methyl | TBDMS | 1 | 1 | Water | | RT | No Reaction | | |
| | Propyl | TBDMS | 1 | 1 | None | None | RT | No Reaction | | |
| | Propyl | TBDMS | 1 | 1 | None | None | 150 C | No Reaction | | |
| | Methyl | TMS | 1 | 1 | None | None | RT | No Reaction | | |
| Extensive diene decomposition was typically observed. Conclusion: After extensive experimentation, the Diels-Alder approach to Key Intermediate 1 was abandoned. | | | | | | | | | | |
| Scheme 3: Robinson Annulation/Elimination ^{6,7} | | | | | | | | | | |
| $\frac{1}{1000} + \frac{1}{1000} + \frac{1}{1000} + \frac{1}{1000} + \frac{1}{1000} + \frac{1}{10000} + \frac{1}{10000000000000000000000000000000000$ | | | | | | | | | | |
| Co | onclusio | on: Th | is seau | ence ar | opears to | be the | most pr | omising | | |
| an | nroach | to aco | llire or | am-eco | le quant | ities of | Kev Int | ermediate | | |
| 1 The good stop of Coheme 2 is still low visible and | | | | | | | | | | |
| 1. | i ne se | cond s | tep of S | Scheme | e 3 18 stil | I IOW Y | ielding a | ina | | |
| pro | oduces | a wide | e variet | ty of sid | de produ | cts. We | e are curi | rently | | |
| res | searchi | ng the | best m | ethod t | o optimi | ze this | reaction | | | |
| | | - | | | - | | | | | |

cheaper methyl version (ethyl crotonate). 2. Completion of Spiromastixone J synthesis. Scheme 4: Ortho Lithiation⁸

below.⁸

- 77 (4), 1021–1030.
- 4913.
- Kumar, A. Chem. Rev. 2001, 101 (1), 1-19.
- 431-434.
- 1946.

Acknowledgements

This research was funded in part by the Summer Undergraduate Research Fellowship. Thank you to the University of New Haven Chemistry Department for their continued support. Thank you to Yale West Campus for the use of their instrumentation. A huge thank you to Dr. Cirillo for all of the support and mentorship you have given me.

Future Work

Optimization of sequence in Scheme 3. We are currently optimizing the reaction conditions on the shortened and

Should sequence in Scheme 3 not provide sufficient amounts of desired Key Intermediate 1, an alternative pathway we have considered but not yet explored is the ortho-lithiation of the resorcilate seen in the Scheme 4

$CI, -90^{\circ}C$ $H_2, Pd-C$

References

Niu, S.; Liu, D.; Hu, X.; Proksch, P.; Shao, Z.; Lin, W. J. Nat. Prod. 2014,

Sala, T.; Sargent, M. V. J. Chem. Soc., Perkin Trans. 1 1981, 855–869. Calo, F.; Richardson, J.; Barrett, A.G.M. Org. Lett. 2009, 11(21): 4910-

Grieco, P.; Nunes, J.; Gaul, M.; J. Am. Chem. Soc. 1990, 112, 4595-4596. Dyke, H.; Elix, J.; Marcuccio, S.; Whitton, A. Aust. J. Chem. 1987, 40,

Marmor, R. J. Org. Chem. 1972, 37 (18), 2901-2904. Mikula, H; Hametner, C.; Froehlich, J. Synth. Commun. 2013, 43, 1939-